Shares of Tokai Pharmaceuticals Inc. (NASDAQ:TKAI) were down 3.3% during trading on Friday . The company traded as low as $5.14 and last traded at $5.29, with a volume of 58,207 shares traded. The stock had previously closed at $5.47.

A number of analysts recently commented on TKAI shares. BMO Capital Markets started coverage on shares of Tokai Pharmaceuticals in a research note on Monday, April 11th. They issued an “outperform” rating and a $11.00 target price for the company. Janney Montgomery Scott restated a “buy” rating and set a $12.00 price objective on shares of Tokai Pharmaceuticals in a research note on Tuesday, April 12th. Finally, Bank of America Corp. assumed coverage on shares of Tokai Pharmaceuticals in a research note on Wednesday, April 6th. They set a “buy” rating and a $16.00 price objective for the company. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. Tokai Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $18.00.

The firm’s market capitalization is $117.77 million. The company’s 50 day moving average is $5.81 and its 200 day moving average is $6.32.

Tokai Pharmaceuticals (NASDAQ:TKAI) last released its earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.50) by $0.01. On average, equities analysts predict that Tokai Pharmaceuticals Inc. will post ($2.00) earnings per share for the current year.

Tokai Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of prostate cancer and other hormonally-driven diseases. The Company’s lead drug candidate, galeterone, is an oral small molecule that utilizes the mechanistic pathways of second-generation androgen signaling inhibitors, while also introducing a third mechanism-androgen receptor degradation.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.